TMPRSS2 and prostate carcinoma: Given the key role of fusion protein TMPRSS2-ERG in regulation of IGF1R gene expression, we decided to evaluate next the hypothesis that IGF1R targeted therapy might be more effective in prostate cancer cells expressing the fusion protein in comparison to cells that do not express the chimera.